柳軍，女，現(xiàn)任中國(guó)藥科大學(xué)新藥篩選中心副研究員。1994年7月獲中國(guó)藥科大學(xué)中藥藥理專業(yè)學(xué)士學(xué)位；1995-1996年在中科院上海藥物所藥理室任研究助理；1998-2001年在美國(guó)佛羅里達(dá)大學(xué)醫(yī)學(xué)院任研究助理，從事分子生物學(xué)研究；2003年獲美國(guó)加州州立大學(xué)生物化學(xué)碩士學(xué)位；2011年獲中國(guó)藥科大學(xué)藥理學(xué)專業(yè)博士學(xué)位；2014年1月至2015年2月先后在美國(guó)Dartmouth學(xué)院和Wisconsin醫(yī)學(xué)院進(jìn)行訪問(wèn)學(xué)者交流，從事腫瘤免疫學(xué)研究。

研究方向：代謝藥理。主要從事代謝性疾�。ㄌ悄虿『透哐�脂癥）藥物的機(jī)制研究、相關(guān)靶點(diǎn)尋找與確證、藥物篩選模型和篩選新技術(shù)的建立以及新藥開發(fā)。具體研究?jī)?nèi)容包括針對(duì)高血脂及其誘發(fā)的動(dòng)脈粥樣硬化，開展膽固醇代謝調(diào)控的信號(hào)轉(zhuǎn)導(dǎo)途徑、分子調(diào)控網(wǎng)絡(luò)及相關(guān)藥物機(jī)制研究；基于胰島b-細(xì)胞的保護(hù)和再生作用的天然產(chǎn)物的發(fā)現(xiàn)及系統(tǒng)性評(píng)價(jià)。近年來(lái)，針對(duì)新發(fā)現(xiàn)的免疫檢查點(diǎn)蛋白VISTA，開展腫瘤免疫及自身免疫性疾病的分子機(jī)制及新藥發(fā)現(xiàn)研究，相關(guān)研究成果已發(fā)表于PNAS。

作為主要成員參與國(guó)家“十五”重大專項(xiàng)“新藥篩選平臺(tái)技術(shù)研究、國(guó)家“十五”重大專項(xiàng)“新型高通量篩選模型、化合物庫(kù)建設(shè)和藥物篩選”、國(guó)家“十一五”科技重大專項(xiàng)“新藥篩選核心技術(shù)規(guī)范化平臺(tái)建設(shè)及其科學(xué)應(yīng)用”的研究，還承擔(dān)多項(xiàng)國(guó)家自然科學(xué)基金和省部級(jí)科研項(xiàng)目。已發(fā)表論文70余篇，其中SCI論文50余篇，參編英文專著1部；申請(qǐng)專利10項(xiàng)，其中獲得授權(quán)專利1項(xiàng)。

代表性論文：

1.Jun Liu, Ying Yuan, Wenna Chen, Juan Putra, Arief A. Suriawinata, Austin D. Schen, Halli Miller, Indira Guleria, Richard J. Barth, Yina H. Huang, Li Wang. Non-redundant regulation of murine T cell responses by VISTA and PD-1 immune-checkpoints.PNAS 2015, 112 (21): 6682-66873. (IF 9.674)
 
2.Li Wang, Isabella Le Mercier, Juan Putra, Wenna Chen, Jun Liu, et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.PNAS 2014, 111(41): 14846-51. (IF 9.674)
 
3. Xue Wang, Yupeng Chen, Daoud Waseem Hassan, Hongbin Sun, Jun Liu*. Combination Therapy with Oleanolic Acid and Metformin as a Synergistic Treatment for Diabetes. Journal of Diabetes Research. 2015, doi: 10.1155/2015/973287. (IF 2.164)
 
4.Xue Wang,  Qian Lu, Dongsheng Yu,  Yupeng Chen, Jing Shang, Luyong Zhang, Hongbin Sun, Jun Liu*. Asiatic acid mitigates hyperglycemia and reduces islet fibrosis in Goto-Kakizaki rat, a spontaneous type 2 diabetic animal model. Chinese Journal of Natural Medicines 2015, 13(7): 0529−0534. (IF 1.114)
 
5.Jun Liu, Xue Wang, Yupeng Chen, Lifei Mao, Jing Shang, Hongbin Sun*, Luyong Zhang*. Maslinic acid modulates glycogen metabolism by enhancing the insulin signaling pathway and inhibiting glycogen phosphorylase. Chinese Journal of Natural Medicines 2014，12 (4): 0259−0265. (IF 1.114)
 
6.Liying, Zhang, Xiaojian Jia, Jizhe Dong, Dongyin Chen, Jun Liu*, Luyong Zhang, Xiaoan Wen*. Synthesis and Evaluation of Novel Oleanolic Acid Derivatives as Potential Antidiabetic Agents.Chemical Biology & Drug Design 2014, 83, 297-305. (IF 2.485)
 
7.Liying Zhang, Yingxia Zhang, Jizhe Dong, Jun Liu*, Luyong Zhang, Hongbin Sun*. Design and synthesis of novel photoaffinity probes for study of the target proteins of oleanolic acid. Bioorganic & Medicinal Chemistry Letters 2012, 22, 1036-1039. (IF 2.420)
 
8.Lei Zhang, Xiaojie Chen, Jun Liu, Qingzhang Zhu, Ying Leng, Xiaomin Luo, Hualiang Jiang, Hong Liu*. Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase. European journal of medicinal chemistry 2012, 58, 624-639. (co-first author)  (IF 3.447)
 
9.Jun Liu, Ting He, Qian Lu, Jing Shang, HB Sun, Luyong Zhang. Asiatic acid preserves beta mass and mitigates hyperglycemia in streptozocin-induced diabetic rats. Diabetes Metabolism Research and Reviews 2010, 26, 448-454. (IF 3.553)
 
10.Jun Liu, Hongbin Sun, Weigang Duan, Luyong Zhang. Maslinic acid reduces blood glucose and body weight in KK-Ay mice. Biological & Pharmaceutical Bulletin 2007, 30, 2075-2078. (IF 1.828)

11.Gary A. Visner, Fuhua Lu, Hailan Zhou, Jun Liu, Kristy Kazemfar, and Anupam Agarwal. Rapamycin Induces Heme Oxygenase-1 in Human Pulmonary Vascular Cells: Implications in the Antiproliferative Response to Rapamycin. Circulation 2003, 107, 911–916. (IF 14.430)

聯(lián)系方式

Tel：025-83271043；Email：junliu@cpu.edu.cn

通信地址：南京市童家巷24號(hào)，中國(guó)藥科大學(xué)新藥篩選中心，郵編210009